Effect of Bumetanide on Facial Nerve Regeneration in Rat Model. (January 2021)

• Record Type: Journal Article
• Authors: Longur, Ecem Sevim; Yiğit, Özgür; Kalaycık Ertugay, Çiğdem; Araz Server, Ela; Adatepe, Turgut; Akakın, Dilek; Orun, Oya; Karagöz Köroğlu, Ayça
• Is Part Of: Otolaryngology--head and neck surgery. Volume 164:Number 1(2021)
• Page Start: 117
• Page End: 123
• Publication Date: 2021-01
• Subjects: aquaporin -- bumetanide -- facial paralysis -- regeneration; Head -- Surgery -- Periodicals; Neck -- Surgery -- Periodicals; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1177/0194599820937670
• Languages: English
• ISSNs: 0194-5998

Abstract

Objective: We investigated the effects of bumetanide alone and in combination with dexamethasone on facial nerve regeneration in rats with facial paralysis. Study Design: A prospective controlled animal study. Setting: An animal laboratory. Subjects and Methods: Facial paralysis was induced in 32 Wistar rats that we then divided into 4 groups: group 1, control; group 2, bumetanide; group 3, dexamethasone; group 4, bumetanide and dexamethasone. Electroneurography was performed 1, 2, and 4 weeks later, and nerve regeneration was evaluated by electron and light microscopy and Western blotting in week 4. Results: Regarding the comparison between preoperative values and week 4, the latency difference in group 1 (1.25 milliseconds) was significantly higher than those of groups 2 to 4 (0.56, 0.34, and 0.10 milliseconds, respectively; P = .001). The latency increment in groups 2 and 3 was higher than that of group 4 ( P = .002 and P = .046) in week 4, whereas groups 2 and 3 did not differ significantly ( P = .291). Amplitude difference was not statistically significant from week 4 among all groups (all P > .05). The number of myelinated axons was significantly higher in all treatment groups than in the control group ( P = .001). Axon number and intensity were significantly higher in group 4 as compared with groups 2 and 3 ( P = .009, P = .005). Conclusion: After primary neurorrhaphy, dexamethasone and bumetanide alone promoted nerve recovery based on electrophysiologic and histologic measures. Combination therapy was, however, superior.